30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 - 2016/17.
Adult
Antihypertensive Agents
/ therapeutic use
Body Mass Index
Cardiovascular Diseases
/ epidemiology
Cigarette Smoking
/ epidemiology
Cross-Sectional Studies
Czech Republic
/ epidemiology
Female
Health Knowledge, Attitudes, Practice
Health Surveys
Humans
Hypercholesterolemia
/ epidemiology
Hypertension
/ drug therapy
Male
Middle Aged
Morbidity
/ trends
Mortality
/ trends
Obesity
/ epidemiology
Politics
Risk Factors
Social Change
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
02
2020
accepted:
22
04
2020
entrez:
12
5
2020
pubmed:
12
5
2020
medline:
6
8
2020
Statut:
epublish
Résumé
Compared with Western Europe, the decline in cardiovascular (CV) mortality has been delayed in former communist countries in Europe, including the Czech Republic. We have assessed longitudinal trends in major CV risk factors in the Czech Republic from 1985 to 2016/17, covering the transition from the totalitarian regime to democracy. There were 7 independent cross-sectional surveys for major CV risk factors conducted in the Czech Republic in the same 6 country districts within the WHO MONICA Project (1985, 1988, 1992) and the Czech post-MONICA study (1997/98, 2000/01, 2007/08 and 2016/2017), including a total of 7,606 males and 8,050 females. The population samples were randomly selected (1%, aged 25-64 years). Over the period of 31/32 years, there was a significant decrease in the prevalence of smoking in males (from 45.0% to 23.9%; p < 0.001) and no change in females. BMI increased only in males. Systolic and diastolic blood pressure decreased significantly in both genders, while the prevalence of hypertension declined only in females. Awareness of hypertension, the proportion of individuals treated by antihypertensive drugs and consequently hypertension control improved in both genders. A substantial decrease in total cholesterol was seen in both sexes (males: from 6.21 ± 1.29 to 5.30 ± 1.05 mmol/L; p < 0.001; females: from 6.18 ± 1.26 to 5.31 ± 1.00 mmol/L; p < 0.001). The significant improvement in most CV risk factors between 1985 and 2016/17 substantially contributed to the remarkable decrease in CV mortality in the Czech Republic.
Sections du résumé
BACKGROUND
Compared with Western Europe, the decline in cardiovascular (CV) mortality has been delayed in former communist countries in Europe, including the Czech Republic. We have assessed longitudinal trends in major CV risk factors in the Czech Republic from 1985 to 2016/17, covering the transition from the totalitarian regime to democracy.
METHODS
There were 7 independent cross-sectional surveys for major CV risk factors conducted in the Czech Republic in the same 6 country districts within the WHO MONICA Project (1985, 1988, 1992) and the Czech post-MONICA study (1997/98, 2000/01, 2007/08 and 2016/2017), including a total of 7,606 males and 8,050 females. The population samples were randomly selected (1%, aged 25-64 years).
RESULTS
Over the period of 31/32 years, there was a significant decrease in the prevalence of smoking in males (from 45.0% to 23.9%; p < 0.001) and no change in females. BMI increased only in males. Systolic and diastolic blood pressure decreased significantly in both genders, while the prevalence of hypertension declined only in females. Awareness of hypertension, the proportion of individuals treated by antihypertensive drugs and consequently hypertension control improved in both genders. A substantial decrease in total cholesterol was seen in both sexes (males: from 6.21 ± 1.29 to 5.30 ± 1.05 mmol/L; p < 0.001; females: from 6.18 ± 1.26 to 5.31 ± 1.00 mmol/L; p < 0.001).
CONCLUSIONS
The significant improvement in most CV risk factors between 1985 and 2016/17 substantially contributed to the remarkable decrease in CV mortality in the Czech Republic.
Identifiants
pubmed: 32392239
doi: 10.1371/journal.pone.0232845
pii: PONE-D-20-04207
pmc: PMC7213700
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0232845Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Public Health. 2008 Jun 05;8:200
pubmed: 18533989
N Engl J Med. 1991 Mar 14;324(11):739-45
pubmed: 1997840
Atherosclerosis. 2010 Aug;211(2):676-81
pubmed: 20471016
Eur Heart J. 1997 Dec;18(12):1231-48
pubmed: 9508543
Lancet. 1999 May 8;353(9164):1547-57
pubmed: 10334252
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Eur J Public Health. 2015 Jun;25(3):539-46
pubmed: 25422363
Lancet. 2017 Jan 7;389(10064):37-55
pubmed: 27863813
Circulation. 2016 May 17;133(20):1916-26
pubmed: 27006480
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Int J Epidemiol. 2020 Feb 1;49(1):173-192
pubmed: 31321439
Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
JAMA. 2017 May 16;317(19):1955-1957
pubmed: 28510660
CMAJ. 2008 May 20;178(11):1441-9
pubmed: 18490640
BMC Public Health. 2016 Aug 04;16:717
pubmed: 27492379
Eur J Prev Cardiol. 2017 Apr;24(6):612-620
pubmed: 27794107
Circulation. 2009 Jul 7;120(1):86-95
pubmed: 19528335
Hypertension. 1996 May;27(5):1065-72
pubmed: 8621198
Elife. 2016 Jul 26;5:
pubmed: 27458798
Public Health Nutr. 2001 Oct;4(5):999-1003
pubmed: 11784413
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113
pubmed: 17726407
Eur J Cardiovasc Prev Rehabil. 2011 Jun;18(3):347-59
pubmed: 21450659
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
Eur J Cardiovasc Prev Rehabil. 2006 Feb;13(1):104-14
pubmed: 16449873
J Epidemiol Community Health. 2004 Jun;58(6):481-5
pubmed: 15143116
Eur J Prev Cardiol. 2014 Jul;21(7):829-39
pubmed: 23180867